- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02274363
A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis
23. mars 2017 oppdatert av: Janssen Pharmaceutica
Assessment of Psoriasis Severity in Brazilians Patients With Chronic Plaque-type Psoriasis Attending Outpatient Clinics: a Multicenter, Observational, and Cross-sectional Study (APPISOT)
The purpose of this study is to assess the severity of plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches.
The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region) in brazilian participants with chronic plaque-type psoriasis.
Studieoversikt
Detaljert beskrivelse
This is a cross-sectional (studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time), observational (clinical study in which participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to specific interventions), non-interventional, multicenter study (when more than one hospital or medical school team work on a medical research study).
Participants with plaque psoriasis will be followed up at specialized dermatology centers.
Participants will undergo assessment at a single time point and all assessments will be conducted on the same day.
Information will be collected about disease severity/ socioeconomic variables and demographics; clinical characteristics; treatment (current and past procedures and therapies to treat psoriasis); quality of life; and comorbidities identified after plaque psoriasis was diagnosed.
The information will be obtained from the medical records, as requested, and during the medical interviews.
The primary objective of this study is to assess the severity of plaque-type psoriasis.
Studietype
Observasjonsmessig
Registrering (Faktiske)
1131
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Belem, Brasil
-
Belo Horizonte, Brasil
-
Botucatu, Brasil
-
Brasilia, Brasil
-
Campinas, Brasil
-
Curitiba, Brasil
-
Fortaleza, Brasil
-
Goiania, Brasil
-
Joao Pessoa, Brasil
-
Porto Alegre, Brasil
-
Ribeirão Preto, Brasil
-
Rio De Janeiro, Brasil
-
Salvador, Brasil
-
Santo Andre, Brasil
-
Sao Jose Do Rio Preto, Brasil
-
Sao Paulo, Brasil
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Participants at least 18 years of age with chronic plaque psoriasis under outpatient follow-up will be included irrespective of disease severity.
Beskrivelse
Inclusion Criteria:
- Participant diagnosed with chronic plaque psoriasis
- Participant is at least 18 years old
- Participant is able to understand and sign the Informed Consent Form
Exclusion Criteria:
- In the opinion of the investigator, the participant is unable or unavailable to complete all study procedures
- Participant suffers from a psychiatric condition or any other clinical condition that might interfere with the ability to understand the study requirements
- Participant refuses consent or is unwilling to supply the required information within the required period
- Participant is taking part in an interventionist clinical trial with an investigational agent (i.e. non-commercialized agent) or in an interventionist clinical trial sponsored by Johnson & Johnson
- Participant is an employee of the investigator or study site and is directly involved in the conduction of this study or other studies conducted by the same investigator at the same site, or is a family member of the employee or investigator
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: Kohort
- Tidsperspektiver: Tverrsnitt
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
Brazilian Participants with Chronic Plaque-type Psoriasis
Brazilian participants with plaque psoriasis followed up at teaching and non-teaching specialized dermatology centers will be included in this study.
|
Participants will not receive any intervention in this study.
Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque-type psoriasis Participants will not be followed over time.
Data will be collected from the medical consultation notes, medical records and during interviews.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Participant's Psoriasis Severity
Tidsramme: At single study visit anytime between 6 to 12 months
|
Psoriasis severity will be graded as mild or moderate to severe based on psoriasis area and severity index (PASI) score;combined assessment of lesion severity and area affected into single score.
Body will be divided into 4 sections:head, arms, trunk, and legs.
For each section, percent (%) area of skin involved was estimated:0=0%, 1=less than (<) 10%, 2=10 to <30%, 3=30 to <50%, 4=50 to <70%, 5=70 to <90%, 6=90 to 100%.
Severity will be estimated by clinical signs:erythema,induration,desquamation;scale:0= none to 4=maximum.
Final PASI=sum of severity parameters for each section*area score*weight of section (head:0.1,arms:0.2,body:0.3,legs:0.4);total
possible score range: 0=no disease to 72=maximal disease or on the dermatology life quality index (DLQI);comprises 10 questions evaluated on a scale from 0 (not at all) to 3 (very much).
The total scores may range from 0 to 30, with higher scores indicating a higher level of disability or on body surface area (BSA).
|
At single study visit anytime between 6 to 12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Participant Current Psoriasis Severity
Tidsramme: At single study visit anytime between 6 to 12 months
|
Psoriasis severity will be graded as mild or moderate to severe based on psoriasis area and severity index (PASI) score or on the dermatology life quality index (DLQI) or on body surface area (BSA).
Participants with a score greater than (>) 10 in any of these scales will be reported as moderate to severe psoriasis.
Participants with a PASI score less than or equal to (<=) 10 will be reported as mild psoriasis.
Assessment should consider the participant's status at inclusion.
|
At single study visit anytime between 6 to 12 months
|
Disease Duration
Tidsramme: Time from disease diagnosis to inclusion (up to 12 months)
|
Disease duration is the time from disease diagnosis to inclusion in the study.
|
Time from disease diagnosis to inclusion (up to 12 months)
|
Hospital Anxiety and Depression Scale (HADS) Score
Tidsramme: At single study visit anytime between 6 to 12 months
|
The HADS has been developed to identify symptoms of anxiety and depression in hospitalized participants and in outpatients.
It comprises 14 items, seven to assess anxiety (HADS-A), namely items 1, 3, 5, 7, 9, 11, and 13; and seven to assess depression (HADS-D), namely items 2, 4, 6, 8, 10, 12, and 14.
Each item receives a score from 0 to 3 on a Likert Scale.
The total score for each scale is obtained by adding the individual scores for each item, with the maximum score 21.
The presence or absence of depression and anxiety will be defined, for each respective scale, based on the following cutoff values: HADS (anxiety): 0-8 = no anxiety; >9 = anxiety; HADS (depression): 8-8 = no depression; >9 = depression.
|
At single study visit anytime between 6 to 12 months
|
Brief Pain Inventory (BPI) Scale Score
Tidsramme: At single study visit anytime between 6 to 12 months
|
The presence of pain or discomfort over the past week will be assessed using the BPI.
The BPI consists of 9 items related to pain (items 3 to 6) and the impact of pain/discomfort (items 9a to 9g) on general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life.
Each item is assessed on an 11-point scale varying from zero (no pain or no impact) to 10 (worst possible pain/worst possible impact).
The items cover the dimensions of pain/discomfort severity and impact, and the scores are calculated from the means of each item, and may range from 0 to 10.
The higher the score, the worse is the pain/discomfort and the perceived impact.
|
At single study visit anytime between 6 to 12 months
|
Health Related Quality of Life (HRQoL) Score
Tidsramme: At single study visit anytime between 6 to 12 months
|
The HRQoL will be assessed using 36-Item Short-Form Health Survey (SF-36), to assess global HRQoL; and the Dermatology Life Quality Index (DLQI) to assess quality of life specifically related to dermatological conditions.
The SF-36 comprises 36 questions divided in 8 domains: physical functioning (10 items), role-physical (4 items), bodily pain (2 items), general health (5 items), vitality (4 items), social functioning (2 items), role-emotional (3 items), mental health (5 items), and a question for comparative assessment of current health status with that of the previous year.
The domain-specific scores range from 0 (worst status) to 100 (best status).
DLQI comprises 10 questions evaluated on a scale from 0 (not at all) to 3 (very much).
The total scores may range from 0 to 30, with higher scores indicating a higher level of disability.
|
At single study visit anytime between 6 to 12 months
|
Number of Participants With Alcohol Abuse
Tidsramme: At single study visit anytime between 6 to 12 months
|
Disorders related to alcohol abuse will be investigated using the cut down, annoyed by criticism, guilty and eye-opener (CAGE) questionnaire.
CAGE is a brief questionnaire that comprises four questions to be answered affirmatively or negatively.
Two affirmative answers warrant a screening for alcohol abuse or dependence.
|
At single study visit anytime between 6 to 12 months
|
Number of Participants With Comorbidities
Tidsramme: At single stuy visit anytime between 6 to 12 months
|
Comorbidity refers to the presence of co-existing or additional diseases with reference to an initial diagnosis or with reference to the index condition that is the subject of study.
Participants with Crohn's disease, systemic arterial hypertension, hyperlipidemia, arthritis, obesity, pruritus/burning sensation, depression, ulcerative colitis, metabolic syndrome, neoplasia, diabetes mellitus, ischemic disease and other cardiovascular disorders will be reported.
|
At single stuy visit anytime between 6 to 12 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
10. april 2012
Primær fullføring (Faktiske)
31. mai 2013
Studiet fullført (Faktiske)
31. mai 2013
Datoer for studieregistrering
Først innsendt
22. oktober 2014
Først innsendt som oppfylte QC-kriteriene
22. oktober 2014
Først lagt ut (Anslag)
24. oktober 2014
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
27. mars 2017
Siste oppdatering sendt inn som oppfylte QC-kriteriene
23. mars 2017
Sist bekreftet
1. mars 2017
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CR100727
- CNTO1275PSY0001 (Annen identifikator: Janssen Pharmaceutica)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Ja
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Psoriasis
-
ProgenaBiomeRekrutteringPsoriasis | Psoriasis Vulgaris | Psoriasis i hodebunnen | Psoriatisk plakk | Psoriasis Universalis | Psoriasis ansikt | Psoriasis negl | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaForente stater
-
Clin4allRekrutteringPsoriasis i hodebunnen | Psoriasis negl | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrankrike
-
Centre of Evidence of the French Society of DermatologyRekrutteringPsoriasis | Psoriasis Vulgaris | Psoriasis i hodebunnen | Psoriatisk plakk | Psoriasis Universalis | Psoriasis Palmaris | Psoriatisk erytrodermi | Psoriasis negl | Psoriasis Guttate | Psoriasis invers | Psoriasis pustulærFrankrike
-
AmgenFullførtPsoriasis-type psoriasis | Plakk-type psoriasisForente stater
-
Innovaderm Research Inc.FullførtPsoriasis i hodebunnen | Pustuløs Palmo-plantar Psoriasis | Ikke-pustulær Palmo-plantar Psoriasis | Psoriasis i albuen | Psoriasis i underbenetCanada
-
UCB Biopharma S.P.R.L.FullførtModerat til alvorlig psoriasis | Generalisert pustuløs psoriasis og erytrodermisk psoriasisJapan
-
TakedaRekrutteringGeneralisert pustulær psoriasis | Erytrodermisk psoriasisJapan
-
Janssen Pharmaceutical K.K.RekrutteringGeneralisert pustulær psoriasis | Erytrodermisk psoriasisJapan
-
Eli Lilly and CompanyFullførtGeneralisert pustulær psoriasis | Erytrodermisk psoriasisJapan
-
PfizerFullførtPsoriasis Vulgaris | Pustuløs psoriasis | Psoriasis Arthropathica | Erytrodermisk psoriasisJapan
Kliniske studier på No Intervention
-
Thomas Jefferson UniversityRekrutteringProstata karsinomForente stater
-
Oregon Research InstituteFullført
-
Sarah BlaylockVA Office of Research and DevelopmentFullførtFalle | LavsynForente stater
-
Tel Aviv UniversityFullført
-
Thomas Jefferson UniversityFullførtHematopoetisk og lymfoid celle-neoplasma | Ondartet fast neoplasmaForente stater
-
University Hospital, BonnGerman Federal Ministry of Education and ResearchUkjent
-
Idaho State UniversityHar ikke rekruttert ennåEksperimentelle videospill | Atferdsvurdering
-
VA Office of Research and DevelopmentRekruttering
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science UniversityHar ikke rekruttert ennå
-
VA Office of Research and DevelopmentFullført